On December 27, 2023, Spyre Therapeutics, Inc. closed the transaction. The transaction included participation from 30 investors. The company paid finders fee of $10,800,000 in the transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.98 USD | +0.92% | -12.75% | +53.25% |
May. 15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
May. 13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+53.25% | 1.33B | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Spyre Therapeutics, Inc. announced that it has received $180 million in funding from a group of investors